Oragenics, Inc. — 2022 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2022, covering a development-stage biotechnology company with no material product-sales revenue. Its lead program, NT-CoV2-1, is a preclinical intranasal COVID-19 vaccine candidate; its lantibiotics program is also preclinical and targets antibiotic-resistant infections. The financial statements are audited and presented under U.S. GAAP. Share and per-share figures reflect the 1-for-60 reverse split effective January 20, 2023.
Financial performance, liquidity, and debt
| Metric | 2022 | 2021 |
|---|---|---|
| Grant revenue | $131,521 | $86,987 |
| Research and development expense | $10.07 million | $10.59 million |
| General and administrative expense | $4.47 million | $5.27 million |
| Net loss | $14.29 million | $15.71 million |
| Net loss per share, basic and diluted | $7.11 | $8.09 |
| Cash used in operating activities | $15.23 million | $13.47 million |
| Cash and cash equivalents at year-end | $11.43 million | $27.27 million |
Grant revenue was the only reported revenue; the filing does not report product sales. Gross or operating margins are not meaningful for this pre-revenue business. Operating expenses totaled $14.55 million. The net loss narrowed about 9.1%, as operating expenses fell 8.3% and other income increased.
At December 31, 2022, current assets were $14.29 million, current liabilities $1.60 million, and working capital $12.69 million. Total assets were $14.76 million and shareholders’ equity was $13.01 million. Short-term notes payable were $267,640; the company also reported operating lease liabilities of $356,886 in total. The filing reports no off-balance-sheet arrangements.
Operating cash use exceeded the prior year despite a lower net loss, driven in part by a $1.90 million increase in prepaid expenses and other current assets. Year-end prepaid expenses and other current assets were $2.86 million, including approximately $2.4 million paid to vendors for research and development work not yet completed. Net financing cash flow was a use of $494,916 in 2022, compared with $23.14 million provided in 2021, when the company raised substantial equity proceeds.
Material changes versus the prior comparable period
- R&D expense declined 4.9% and G&A expense declined 15.1%. Management attributed the R&D decrease mainly to payments for work not yet completed being recorded as prepaid expenses; lower stock-based compensation, board fees, and salaries contributed to lower G&A.
- Cash fell by $15.84 million during 2022, from $27.27 million to $11.43 million. Working capital declined from $26.26 million to $12.69 million.
- In 2022, the company converted portions of Series A and Series B preferred stock into common stock and raised approximately $69,000 gross through its ATM program. The prior year included approximately $26.7 million in net ATM proceeds and other financing cash flows.
- After year-end, the company completed a 1-for-60 reverse split to address NYSE American’s low-share-price deficiency and reported regaining listing compliance on February 3, 2023.
Outlook, risks, contingencies, and unusual items
- Management expected year-end 2022 cash to fund operations as then structured through the fourth quarter of 2023. It said cost-saving measures, if implemented, could extend the runway into the first quarter of 2024. The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Management anticipated filing an IND in the United States and/or a Clinical Trial Application in Canada and starting a Phase 1 NT-CoV2-1 study in the second half of 2023. Further development was contingent on additional financing, grants, partnering, or out-licensing. The filing does not establish that these milestones were achieved.
- Management reported completion of the rabbit GLP toxicology study in 2022 and described the findings as supportive of proceeding toward a Phase 1 study. Earlier animal studies showed immune responses and reduced viral loads; these preclinical findings do not establish human safety or efficacy.
- The company said limited funding would reduce its lantibiotics research, manufacturing-optimization, and preclinical work until additional capital is raised. It reported a $250,000 SBIR grant award for lantibiotics research and disclosed that its BARDA funding application was denied.
- On February 23, 2023, the company entered an exclusive global license for Inspirevax’s BDX301 intranasal adjuvant, with a $50,000 upfront fee, milestone payments, and royalties. On February 24, 2023, it entered a new ATM agreement; proceeds, if any, were intended for development programs and general corporate purposes.
- On April 4, 2023, management and the Audit Committee concluded that the Q1, Q2, and Q3 2022 interim financial statements should no longer be relied upon. The error involved research and development contract payments that should have been recorded as prepayments rather than expenses. Amendments were filed April 14, 2023. Management identified a material weakness in review of R&D contracts and concluded controls were not effective; remediation was underway, with no assurance as to timing or success.
- Other key risks include the need to raise capital, potential dilution and limited authorized common shares, dependence on licensors and contract manufacturers, regulatory and clinical uncertainty, competition and changing COVID-19 demand, and the ability to scale lantibiotic production. The filing states there were no material legal proceedings.
Important facts for investors to verify
- Current cash runway, actual spending, cost reductions, and whether additional financing has been secured; the reported runway estimates are management expectations, not guarantees.
- Status of the NT-CoV2-1 regulatory filing and Phase 1 trial, and whether required manufacturing, formulation, and adjuvant arrangements are complete.
- Progress on remediation of the material weakness and whether subsequent filings or audits identify further accounting errors.
- Current common shares authorized and outstanding, remaining ATM capacity, potential dilution from options, warrants, and preferred stock, and continued NYSE American listing compliance.
- Whether preclinical lantibiotics findings translate into a funded lead candidate, scalable manufacturing, and a path to IND filing.